Within this, the herbal sleep segment is expected to nearly quadruple in sales from 70 million in 2017 to 323 million in 2025.” “According to NBJ’s 2022 Condition Specific Report, consumers spent approximately $600 million on supplements for sleep in 2017, and by 2025 that number is expected to surge to nearly $1.6 billion. “The impact of high stress on sleep cannot be undermined,” said Abey Thomas, head of marketing for Natural Remedies, in a press release. Scores from the Athens Insomnia Scale decreased by 48% in the Holixer group, compared to 27% in the placebo group, and data collected from a Fitbit found that supplementation with the herb was associated with a 3.4% increase in sleep efficiency over time. According to Perceived Stress Scale scores, after eight weeks, perceived stress decreased by 37% in subjects taking Holixer, compared to a 19% decrease in the placebo group. The Holixer group showed significantly greater improvements in stress and cortisol levels as well as sleep scores compared to those in the placebo group. “ is made with Bioactive Optimization Technology, yielding a unique profile, Ocimum-Bioactive Complex (OBC), which is a potent collection of different bioactives, creating a unique holy basil ingredient with potent actives,” Reddy explained.Ī 2022 randomized, double-blind, placebo, controlled clinical study 1, published in Frontiers in Nutrition, administered 250 mg/d of Holixer or a placebo for eight weeks to 100 healthy participants who reported stress and poor sleep. Narender Reddy, CEO of Natural Remedies, said in a press release that it took five years to develop Holixer. The release of excess cortisol can impair sleep and immune function. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.Natural Remedies(Bangalore, India) launched Holixer holy basil/tulsi ( Ocimum tenuiflorum), an adaptogen that in vitro and in vivo studies has shown inhibits and/or reduces cortisol release from the adrenal glands in response to stress-induced production of adrenocorticotropic hormone. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. On this news, Sleep Number's stock price fell $14.46 per share, or 12.88%, to close at $97.78 per share on July 21, 2021. The release revealed that Sleep Number had missed consensus estimates on the top and bottom line for the quarter and again blamed the disappointing results in significant part on "near-term supply constraints" and component shortages. Then, on July 20, 2021, Sleep Number issued a press release announcing its financial results for its second fiscal quarter ended June 30, 2021. On this news, Sleep Number's stock price fell $14.80 per share, or 11.85%, to close at $110.13 per share on April 22, 2021. Specifically, the release stated that Sleep Number had "more than $50 million of deliveries (two weeks) shifted out of the quarter due to temporary foam supply constraints," representing nearly 9% of the Company's entire sales for the quarter. The release revealed that Sleep Number had missed consensus sales estimates for the quarter as a result of significant supply chain disruptions. On April 21, 2021, Sleep Number issued a press release announcing its financial results for its first fiscal quarter ended March 31, 2021. The investigation concerns whether Sleep Number and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |